Non Hodgkin Lymphoma News and Research

RSS

Scientists use genetically engineered immune cells to fight Hodgkin and non-Hodgkin lymphoma cells

University of North Carolina Lineberger Comprehensive Cancer Center researchers reported promising early results from a clinical study of an investigational cellular immunotherapy that used a patient's own, genetically engineered immune cells to recognize and fight Hodgkin and non-Hodgkin lymphoma cells.

4 Dec 2018

Amgen announces presentation of new clinical data showcasing early oncology pipeline at ASH 2018

Amgen today announced that new clinical data will be presented at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego, Dec. 1-4, 2018. Data across an array of malignancies will be featured in 45 abstracts, including nine oral presentations, from the Company’s broad portfolio andearly-stage pipeline.

From AMGEN 5 Nov 2018

Head and neck cancer survivors more likely to commit suicide

Despite improved survival rates among cancer patients, the risk of death by suicide remains high, especially among those treated for head and neck cancers.

25 Oct 2018

Organic food may protect against cancers finds study

The study published this week in the latest issue of the journal JAMA Internal Medicine reports that people who consume more organic foods are at a lower overall risk of developing cancer compared to people who do not. Some of the specific cancers avoided are non-Hodgkin lymphoma and postmenopausal breast cancer write the researchers.

23 Oct 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, today announced that it has been selected by Verastem OncologyTM to dispense COPIKTRA (duvelisib) capsules.

28 Sep 2018

FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials

Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies, today announced the U.S. Food and Drug Administration has lifted the partial clinical hold that had paused U.S.-based enrollment of new patients in its tazemetostat clinical trials.

24 Sep 2018

Study reveals how socioeconomic status affects racial, ethnic disparities in childhood cancer survival

A new study provides insights into the degree to which socioeconomic status explains racial and ethnic disparities in childhood cancer survival.

20 Aug 2018

Hospitals battle for control over fast-growing heart-valve procedure

When Medicare in 2011 agreed to pay for a revolutionary procedure to replace leaky heart valves by snaking a synthetic replacement up through blood vessels, the goal was to offer relief to the tens of thousands of patients too frail to endure open-heart surgery, the gold standard.

17 Aug 2018

FDA approves drug for rare, hard-to-treat types of non-Hodgkin lymphoma

The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.

8 Aug 2018

AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia

AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.

20 Jul 2018

CTI BioPharma announces Phase III results of PIXUVRI combined with rituximab in aggressive B-cell NHL patients

CTI BioPharma Corp. and Servier today announced that the pivotal Phase III study evaluating PIXUVRI® combined with rituximab in comparison to gemcitabine combined with rituximab in patients with aggressive B-cell non-Hodgkin lymphoma did not meet its primary endpoint of improvement of progression-free survival

9 Jul 2018

Drug used in stem cell therapy may protect against smoke-induced lung injury

A drug used in stem cell therapy to treat certain cancers may also protect against cigarette smoke-induced lung injury.

5 Jul 2018

Some tumors use two levels of protection against immune system, shows study

In research published today, Babraham Institute researchers have shown that some tumors use not one but two levels of protection against the immune system.

8 Jun 2018

Study finds increase in lifestyle-related cancers over the past decade

Lifestyle-related cancers, such as lung, colorectal, and skin cancers, have increased globally over the past decade, according to the most comprehensive analysis of cancer-related health outcomes and patterns ever conducted.

4 Jun 2018

New 'lymphoma micro-reactor' device targets chemo-resistant tumors

Non-Hodgkin lymphoma, a cancer that is diagnosed in the U.S. more than 70,000 times annually, arises from overly proliferating immune cells within the body's lymph nodes, which are connected to a network of lymph vessels through which lymphatic fluid flows.

12 Apr 2018

New insights into breast implant-associated anaplastic large-cell lymphoma

For the past seven years, the U.S. Food and Drug Administration has reported on cases of a type of lymphoma associated with breast implants.

28 Mar 2018

Researchers propose alternative treatment to target lymphoma signaling at its root

Non-Hodgkin lymphomas are cancers that affect white blood cells of the immune system called B-lymphocytes or B cells. Like cells in all cancers, the B cells begin to grow out of control, creating tumors in the lymph nodes, spleen or other tissues. In 2010 alone, it was estimated that non-Hodgkin lymphomas caused 210,000 deaths worldwide.

22 Mar 2018

Gene-editing technology enhances T cell immunotherapies for treating cancer

Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient's own immune cells -- called T cells -- and supercharging them to home in on and attack specific blood cancers, such as hard-to-treat acute lymphoblastic leukemia and non-Hodgkin lymphoma.

6 Mar 2018

Study reveals HCT as effective treatment for NHL patients regardless of age

Results from a retrospective study of 1,629 patients with non-Hodgkin lymphoma showed that survival at 4 years following allogeneic hematopoietic cell transplantation for patients age 65 years and older is comparable to patients age 55 to 64 years.

21 Feb 2018